Bleeding And Clotting Disorders is an indication for drug development with over 280 pipeline drugs currently active. According to GlobalData, preregistered drugs for Bleeding And Clotting Disorders have a 85.71% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Bleeding And Clotting Disorders compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bleeding And Clotting Disorders overview
Bleeding and clotting disorders are conditions that affect the blood’s ability to coagulate appropriately, leading to either excessive bleeding or inappropriate clotting. Hemophilia, a well-known bleeding disorder, is characterized by a deficiency of clotting factors, resulting in prolonged bleeding even from minor injuries. On the contrary, clotting disorders such as deep vein thrombosis (DVT) or hemostasis imbalance can lead to abnormal clot formation, potentially causing serious conditions like strokes or pulmonary embolisms. These disorders often have a genetic basis, with hemophilia being inherited in an X-linked recessive manner. Treatment involves clotting factor replacement for hemophilia or anticoagulant medications for clotting disorders, aiming to restore balance to the coagulation process. Regular monitoring and medical intervention are crucial for managing these conditions and preventing complications
See Also:
For a complete picture of PTSR and LoA scores for drugs in Bleeding And Clotting Disorders, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
